AB2 Bio signs US licensing deal with Nippon Shinyaku for tadekinig alfa

Privately-held Swiss biotech AB2 Bio has entered into an option and licensing agreement with Japan’s Nippon Shinyaku (TYO: 4519), which it describes as having extensive experience in marketing rare disease therapeutics in the USA.

Under the terms of the agreement, Nippon Shinyaku received an option to acquire exclusive US rights to commercialize tadekinig alfa to treat primary monogenic interleukin (IL)-18 driven hyperinflammatory syndrome, a rare and potentially life-threatening pediatric disease that, if left untreated, may rapidly lead to multiple-organ failure and death.

AB2 Bio will continue to prepare for filing for US Biologics License Application (BLA) approval for tadekinig alfa in the indication.